Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Darolutamide and Stereotactic Body Radiation Therapy in Patients With Castration Resistant Prostate Cancer and Oligometastases on Functional Imaging

NCT06276465 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT06276465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06276465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Darolutamide and Stereotactic Body Radiation Therapy in Patients With Castration Resistant Prostate Cancer and Oligometastases on Functional Imaging
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Recruiting
Start date
October 7, 2024
Completion date
October 7, 2032
Enrollment
336 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic cancer, castration-resistant